Sökning: L773:1532 2238 > Large fat and skin ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03180naa a2200313 4500 | |
001 | oai:lup.lub.lu.se:0f848d03-e6f2-43d8-aff2-cefe48e75334 | |
003 | SwePub | |
008 | 160404s2010 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/17320642 URI |
024 | 7 | a https://doi.org/10.1016/j.ghir.2010.10.0042 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Burman, Piau Lund University,Lunds universitet,Genomik, diabetes och endokrinologi,Forskargrupper vid Lunds universitet,Genomics, Diabetes and Endocrinology,Lund University Research Groups4 aut0 (Swepub:lu)med-bap |
245 | 1 0 | a Large fat and skin necroses after deep subcutaneous injections of a slow-release somatostatin analogue in a woman with acromegaly. |
264 | 1 | b Elsevier BV,c 2010 |
520 | a OBJECTIVE: Somatostatin analogues are the most commonly used drugs for treatment of acromegaly. Known side effects include gastrointestinal reactions, cholelithiasis, effects on glucose metabolism, and mild reactions at injection sites. We report a patient who developed fat and skin necroses after injections of a depot somatostatin analogue. SUBJECT: A woman with active acromegaly was given deep subcutaneous injections of an extended release formulation of lanreotide at alternate sides of the buttocks on three occasions over a ten week period. The regimen was then discontinued due to gastrointestinal complaints. One month later indurated subcutaneous nodules appeared at both sites. After another two months, the patient presented 10×10cm lesions on the buttocks, with central erythematous zones and, at the site of two injections, a necrotic 5×3cm ulcer. There were no signs of infection or systemic diseases. MRI revealed bilateral fat necroses. A month later, an ulcer developed at the second site. The ulcers were managed conservatively until clear demarcations were obtained, where after surgical revisions were performed. Eight months after the last injection, the wounds could be closed. CONCLUSION: The fat and skin necroses represent a side-effect not previously described after deep subcutaneous injections. Possibly, the patient had an exceptional susceptibility to develop an inflammatory, foreign-body like reaction that hypothetically was aggravated by a sustained anti-angiogenic effect of the compound. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Endokrinologi och diabetes0 (SwePub)302052 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Endocrinology and Diabetes0 (SwePub)302052 hsv//eng |
700 | 1 | a Besjakov, Jan4 aut |
700 | 1 | a Svensjö, Tore4 aut |
710 | 2 | a Genomik, diabetes och endokrinologib Forskargrupper vid Lunds universitet4 org |
773 | 0 | t Growth Hormone & Igf Researchd : Elsevier BVg Dec, s. 438-440q Dec<438-440x 1532-2238x 1096-6374 |
856 | 4 | u http://www.ncbi.nlm.nih.gov/pubmed/21071248?dopt=Abstracty FULLTEXT |
856 | 4 | u http://dx.doi.org/10.1016/j.ghir.2010.10.004y FULLTEXT |
856 | 4 8 | u https://lup.lub.lu.se/record/1732064 |
856 | 4 8 | u https://doi.org/10.1016/j.ghir.2010.10.004 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.